Implantable meshes for controlling the movement of fluids
Meshes for use to control the movement of bodily fluids, such as blood, are described herein. The mesh can be partially or completely biodegradable or non-biodegradable. In one embodiment, the mesh is formed from one or more self-assembling peptides. The peptides can be in the form of fibers, such as nanofibers. The peptides can be assembled prior to formation of the mesh or after the mesh has been formed but before it is applied. Alternatively, the mesh can be prepared from unassembled peptides, which assemble at the time of application. The peptides can assemble upon contact with bodily fluids (e.g., blood) or can be contacted with an ionic solution to initiate assembly.
1. A surgical mesh formed from self-assembling peptides or self-assembling peptidomimetics,
wherein the self-assembling peptidomimetics are selected from the group consisting of β-peptides; γ-peptides; δ-peptides; and copolymers of α-peptides, β-peptides; γ-peptides, or δ-peptides,
wherein the surgical mesh is prepared from the self-assembling peptides or self-assembling peptidomimetics by a method selected from the group consisting of freezing of a powder, stamping of a powder, and electrospinning of a solution of the self-assembling peptides or peptidomimetics,
wherein the solution comprises less than 5 mM Li + , Na + , K + and Cs + ions,
wherein the surgical mesh will form a fibrous barrier structure upon contacting the mesh with a concentration of Li+, Na+, K+, or Cs+ ions greater than 5 mM, and
wherein the fibrous barrier structure prevents movement of bodily fluids or contaminants through the structure.
2. The surgical mesh of claim 1 , wherein the self-assembling peptides comprise a sequence of amino acid residues conforming to one or more of Formulas I-IV:
((Xaa neu -Xaa + ) x (Xaa neu -Xaa − ) y ) n (I)
((Xaa neu -Xaa − ) x (Xaa neu -Xaa + ) y ) n (II)
((Xaa + -Xaa neu ) x (Xaa − -Xaa neu ) y ) n (III)
((Xaa − -Xaa neu ) x (Xaa + -Xaa neu ) y ) n (IV)
wherein Xaa neu is an amino acid residue having a neutral charge under physiological conditions; Xaa + is an amino acid residue having a positive charge under physiological conditions; Xaa − is an amino acid residue having a negative charge under physiological conditions; x and y are integers having a value of 1, 2, 3, or 4, independently; and n is an integer having a value of 1-5.
3. The mesh of claim 1 , wherein the self-assembling peptides comprise one or more repeating units of an amino acid sequence selected from the group consisting of AEAKAEAKAEAKAEAK (SEQ ID NO: 56), RADARADARADARADA (SEQ ID NO: 1), RAEARAEARAEARAEA (SEQ ID NO: 58), EAKAEAKAEAKAEAKA (SEQ ID NO. 410), KADAKADAKADAKADA (SEQ ID NO: 59), RARARARADADADADA (SEQ ID NO: 113), RADA (SEQ ID NO: 57), EAKA (SEQ ID NO: 111), and combinations thereof.
4. The mesh of claim 1 , wherein the mesh is partially or completely biodegradable.
5. A device comprising the surgical mesh of claim 1 , and a non-peptide backing material.
6. A device comprising the surgical mesh of claim 1 , and one or more therapeutic, prophylactic, and/or diagnostic agents.
7. The device of claim 6 , wherein the therapeutic, prophylactic, and/or diagnostic agents are selected from the group consisting of hemostatic agents, anti-infectives, growth factors, cells, anesthetics, vasoconstrictors, and combinations thereof.
8. A method for preventing the movement of bodily fluids of a patient, the method comprising applying to or implanting in a patient at a site of traumatic injury or surgery, the surgical mesh of claim 1 .
9. The method of claim 8 , wherein the bodily fluid is blood.
10. The method of claim 8 , wherein the patient suffers from a primary, secondary, or acquired bleeding, or coagulation, or clotting disorder, or wherein the patient is receiving drugs that result in increased bleeding or decreased coagulation as compared to a normal control.
11. The method of claim 8 , further comprising the step of inducing assembly of the self-assembling peptides or peptidomimetics within the surgical mesh by contacting the surgical mesh with a solution having a concentration of greater than 5 mM Li+, Na+, K+ or Cs+ ions.
12. The method of claim 11 , wherein the self-assembling peptides or peptidomimetics are induced to assemble immediately prior to, during or after application of the surgical mesh.
13. The mesh of claim 1 , wherein at least 75% weight/weight (w/w) of the total amount of self-assembling peptides or peptidomimetics in the surgical mesh have the same size and sequence.
14. The method of claim 8 , wherein the surgical mesh is applied to a site of traumatic injury or surgery of an organ selected from the group consisting of the brain, the liver, the stomach, intestine, skin, lung, and heart.
15. The method of claim 10 , wherein the patient has a disease or condition selected from the group consisting of vitamin K deficiency, Von Willebrand disease, hemophilia, congenital afibrinogenemia, Glanzmann's thrombasthenia, Bernard-Soulier syndrome, thrombocytopenia, deficiency in Factor V, deficiency in Factor X, and deficiency in Factor XII.
16. The method of claim 10 , wherein the patient is receiving one or more drugs selected from the group consisting of aspirin, ardeparin, urokinase, warfarin, heparin, and thrombin inhibitors.